NCT07934303
Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of Participants with Treatment-emergent Adverse Events
Timeframe: Day 1 through 48-Week Post-Treatment Follow-Up
Secondary (1)
Change from Baseline in Frataxin Protein Expression
Arms and interventions
Part A: NBIB-223Experimental
Dose escalation in adult participants.
Part B: NBIB-223Experimental
Dose expansion in pediatric participants.
Part C: NBIB-223Experimental
Dose expansion in adult and/or pediatric participants with FA-related cardiomyopathy.
Drugs: NBIB-0000223
Sites
5 sites in 1 country